Vor Biopharma Inc.
No enriched coverage for $VOR in the last 7 days.
No SEC Form 4 filings for $VOR in the last 30 days.
See all $VOR insider activity →Vor Bio (VOR) granted stock options for 59,250 shares and RSUs for 12,550 shares to new hires. Options have a $18.06 exercise price, vesting over four years. RSUs also vest over four years. Grants comply with Nasdaq Rule 5635(c)(4).
Vor Bio completed enrollment in its Phase 3 UPSTREAM MG trial for telitacicept, a treatment for generalized myasthenia gravis, with results expected in early 2027. The company plans to start a Phase 3 trial for ocular myasthenia gravis in the same timeframe, expanding its telitacicept franchise. The trials follow positive results from RemeGen's Phase 3 trial in China.
Biotech stocks rose as several companies issued updates. Wellgistics Health (WGRX) completed a rebrand to DataMEDS AI and will trade as MEDS; it reported Q1 2026 revenue of $0.929M and expects $1.775M in Q2. Dyadic (DYAI) saw a major shareholder sell. Palvella (PVLA) submitted the first NDA module for QTORIN. Sol-Gel (SLGL) expects SGT-610 Phase 3 data in Q4 2026.
Recent VOR coverage spans financial news, corporate actions and technology.
The grant modestly increases share count and may cause slight dilution, but no immediate price catalyst.
Successful enrollment removes a major execution risk and positions the company for topline data in early 2027, potentially driving share price on positive results.
Progress toward Phase 3 topline can sustain momentum, but the next tradable datapoint is still time-distant.
Board-level leadership change may modestly improve investor confidence, but it does not alter near-term clinical/regulatory milestones in the release.
Board refresh via director resignation/appointment; likely limited direct fundamentals impact but can affect governance sentiment and near-term trading flow.
AlphAI scores every news story that mentions VOR with an AI model for sentiment and relevance, and aggregates insider trades from Vor Biopharma Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Vor Bio (VOR) granted stock options for 59,250 shares and RSUs for 12,550 shares to new hires. Options have a $18.06 exercise price, vesting over four years. RSUs also vest over four years. Grants comply with Nasdaq Rule 5635(c)(4).
1 min readVor Bio completed enrollment in its Phase 3 UPSTREAM MG trial for telitacicept, a treatment for generalized myasthenia gravis, with results expected in early 2027. The company plans to start a Phase 3 trial for ocular myasthenia gravis in the same timeframe, expanding its telitacicept franchise. The trials follow positive results from RemeGen's Phase 3 trial in China.
1 min readBiotech stocks rose as several companies issued updates. Wellgistics Health (WGRX) completed a rebrand to DataMEDS AI and will trade as MEDS; it reported Q1 2026 revenue of $0.929M and expects $1.775M in Q2. Dyadic (DYAI) saw a major shareholder sell. Palvella (PVLA) submitted the first NDA module for QTORIN. Sol-Gel (SLGL) expects SGT-610 Phase 3 data in Q4 2026.
6 min readVor Bio (Nasdaq: VOR) appointed David Zaccardelli, Pharm.D., to its Board of Directors. The company said he has led biopharma companies through late-stage development and commercialization, including Verona Pharma until its Oct 2025 acquisition by Merck for $10B. Vor also noted Andrew Levin stepped down as an advisor.
3 min readVor Biopharma Inc. (VOR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K 0001817229 false 0001817229 2026-07-06 2026-07-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 06,
2 min readVor Bio (Nasdaq: VOR) said its Compensation Committee granted inducement awards on July 1, 2026 to seven newly hired employees under Nasdaq Rule 5635(c)(4). Awards include stock options for 71,200 shares (10-year term, $18.39 exercise price) and RSUs for 15,150 shares. Options and RSUs vest over four years subject to continued employment.
2 min readVor Biopharma Inc. (VOR) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. EX-10.1 2 vor-ex10_1.htm EX-10.1 EX-10.1 321452236 v8 Vor Biopharma Inc. Amended and Restated 2021 Equity Incentive Plan Adopted by the Board of Directors: April 16, 2026 Approved by the Stockholders: June 11, 2026 321452236 v8 Table of Contents Page 1. General. 1 2. Shares Subje
2 min readVor Bio (Nasdaq: VOR) said its Compensation Committee granted inducement awards on June 1, 2026 to 10 newly hired employees under Nasdaq Rule 5635(c)(4). The company issued options for 61,050 shares (10-year term, $14.57 exercise price) and RSUs for 12,900 shares. Both vest over four years, subject to continued employment.
2 min readVor Biopharma Inc. (NASDAQ:VOR) experienced a 17.3% decrease in short interest in April, with the total short interest reaching 4,706,707 shares as of April 15th. This represents 9.7% of the company's float, with a days-to-cover ratio of 3.5 days. The stock was trading up 5.6% at midday, reaching $14.81, while analysts maintain a "Moderate Buy" consensus with an average price target of $50.56.
3 min readRA Capital Healthcare Fund LP sold 630,374 shares of Vor Biopharma Inc. (NASDAQ:VOR) common stock for approximately $10.17 million across two transactions in April 2026. Following these sales, RA Capital Healthcare Fund LP retains 2,567,245 shares of Vor Biopharma. The company has recently shifted its focus to autoimmune therapies and initiated a global Phase 3 trial for Sjögren’s disease, while analysts have adjusted price targets but largely maintain positive ratings due to promising drug potential.
3 min read
